Currently, more than 6 million Americans live with Alzheimer’s disease (AD), and it is projected to be 13 million by 2050. AD has no permanent cure yet, and early detection is important to slow down the progress of the disease. Diagnosis is complicated by AD’s similarity to other geriatric diseases. Beta-amyloid peptide (Aβ42), tau proteins and neurofilament light (NFL) measured in the cerebrospinal fluid (CSF) is a reasonably effective method for diagnostics, but very painful for the patients. MicroRNA’s (miRNAs) expressed in the brain are promising biomarkers and our goal of this study is to develop a sensitive and selective point-of-care (POC) test to detect AD specific miRNA (miRNA 30e, 34c and 200c) based on the CRISPR-Cas system. The Cas 13a protein has the regular sequence specific RNase activity followed by a collateral RNase activity. We used this feature of Cas 13a to generate an electrochemiluminescence (ECL) signal by binding specific miRNA biomarkers, and then collaterally cleaving poly-ribose guanine (poly-rG). This cleaved strands of poly-rG and rG itself are coreactants for ECL, and react with ECL polymer Ruthenium Polyvinyl Pyridine (RuPVP) to generate ECL. RuPVP is deposited into pyrolytic graphite (PG) micro wells. Using a 3D-printed microfluidic device equipped with the Pt reference and Ag/AgCl counter electrodes, patient serum mixed with poly-rG is introduced to the RuPVP coated electrode at 1.3 V to provide ECL light measured by a CCD camera. The assay was multiplexed to detect 3 AD specific miRNAs, and obtain a separate calibration for each miRNA biomarker with linear ranges from 70 pg/ mL to 7 µg/mL, from 7.4 pg/ mL to 74 µg/ mL and from 7.4 fg/ mL to 74 µg/ mL for 30e, 34c and 200c respectively. Preliminary LODs were 42 pg/ mL, 0.074 fg/ mL and 0.15 fg/ mL for miRNA 30e, 34c and 200c respectively. Results confirm the sensitivity of the assay. Further, spike recovery, cross reactivity studies and patient sample assays will be reported.
Read full abstract